New data boosts Novo against Sanofi in insulin-market fight

Novo Nordisk ($NVO) has some new data in hand that could help a safety advantage make its way onto the label of new drug Tresiba--and win it points against heavyweight rival Sanofi ($SNY). In a recent study, the med hit its primary endpoint, cutting the number of hypoglycemic events by 30% compared with the French drugmaker's Lantus. Tresiba's rate of hypoglycemia tallied 186 events per 100 patient years, compared with 265 on Lantus. And as for hypoglycemia episodes at night, the study's secondary endpoint, Tresiba slashed them by 42%. More from FiercePharmaMarketing

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.